The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q4 2015 call → NOWe need to determine if management conveys that a major undertaking's heavy phase is done and the collecting phase has begun but is early in the numbers. The transcript mentions several undertakings: ERP implementation, new carbon fiber line in France, Formax acquisition, A350 ramp-up, etc. The most prominent is the ERP system. Wayne Pensky says: "We are very pleased to report that we have now completed the installation of our new ERP system and we look forward to optimizing in 2016 to generate improved efficiencies while we continued to ramp up for our expected growth." That indicates the heavy phase (installation) is done. The collecting phase? He says "look forward to optimizing in 2016 to generate improved efficiencies" - that suggests benefits are future, not yet begun. Also, they spent nearly $10 million more in IT in 2015, and they expect to continue spending on ERP in 2016. So the payoff is not yet visible. Also, the reported results still carry the burden? They said IT expenses were higher in 2015, and they will continue to spend. So the heavy phase is done, but the collecting phase hasn't begun in numbers. The question asks: "has now entered the phase where the company COLLECTS on that completed work, with the reported results still mostly reflecting the paying phase rather than the collecting phase?" Management says they completed installation and look forward to optimizing to generate efficiencies. That implies the collecting phase is about to start, but not yet begun. They don't say that benefits are starting to arrive. They say "look forward to" - future. So answer NO. Another possible undertaking: the new carbon fiber line in France. Nick says: "Our construction of a new carbon fiber and pan line in France is now full throttle, on schedule and on budget. And we expect to make significant progress in 2016 so that we can start the qualification process next year." That means the heavy phase is still ongoing (full throttle), and qualification is next year. So not done. Formax acquisition: completed in early January. But that's an acquisition, not a heavy phase. The integration is ongoing. They say "look forward to fully integrating their technology" - so still in heavy phase. A350 ramp-up: they are in the middle of ramping up, not done. Thus, no clear situation where heavy phase is done and collecting has begun but early.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.